Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission

Inclusion Criteria:

• Subjects should have a definitive diagnosis of Crohn's disease, based on WHO criteria

• Males and females ≥ 18 years old, including women who are not pregnant or lactating atthe time of enrollment.

• Subjects should have a CDAI score ≥ 150 at week 0

• Able to swallow tablets

• Are capable of providing written informed consent and obtained at the time ofenrollment

• Willing to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

• Bacterial,viral or other microbial infection(including HIV)

• Needing orally administered corticosteroids for the treatment of other diseases.Inhaled or dermatologic preparations are acceptable.

• Previous or current use of infliximab. current use of prescription doses orchronic/frequent use of NSAIDs

• Treatment with narcotic pain medications. (Anti-diarrheal agents such as loperamideand diphenoxylate are permitted)

• History of pancreatitis, except for subjects with a known but removed cause(such asgallstone pancreatitis)

• History of abnormal liver function tests, including AST or ALT >1.5 times upper limitof normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5mg/dL at screening (or within the previous 6 months, if known)

• History of malignancy

• Women who are pregnant or lactating at the time of enrollment, or who intend to beduring the study period.

• Participation in other clinical trial within the past 6 months